自体移植后第二原发恶性肿瘤对多发性骨髓瘤结局的影响:一项CIBMTR分析
该研究利用CIBMTR登记数据,纳入2011至2018年在美国接受首次auto-HSCT并以美法仑预处理后接受维持治疗的3948例成人多发性骨髓瘤患者。中位随访37个月时,175例(4%)发生第二原发恶性肿瘤(SPM),多因素分析显示SPM与SHM均与更差的PFS和OS相关。作者认为SPM和SHM导致生存不良,是重要的生存挑战,鉴于骨髓瘤中位生存不断改善,需持续警惕移植后维持治疗相关的SPM和SHM风险。
要点
- 中位随访37个月,3948例中175例(4%)发生SPM,其中实体瘤112例(64%)、髓系肿瘤36例(20%)。
- 多因素分析:SPM与更差PFS相关(HR 2.62,P < .001),SHM与更差PFS相关(HR 5.01,P < .001)。
- SPM与更差OS相关(HR 3.85,P < .001),SHM与更差OS相关(HR 8.13,P < .001)。
核心结论
- SPM和SHM的发生导致多发性骨髓瘤患者生存不良,是重要的生存挑战。
- 鉴于骨髓瘤中位生存持续改善,需持续警惕auto-HSCT后维持治疗相关的SPM和SHM风险。
研究设计与样本
- 利用CIBMTR登记数据进行的分析,纳入2011至2018年在美国接受首次auto-HSCT、以美法仑为预处理方案并接受维持治疗的成人多发性骨髓瘤患者(n = 3948)。
主要发现
- 中位随访37个月,175例(4%)患者发生SPM,包括实体瘤112例(64%)、髓系肿瘤36例(20%)、非特指第二血液系统恶性肿瘤(SHM)24例(14%)和淋系恶性肿瘤3例(2%)。
- 多因素分析显示,SPM与更差的PFS相关(HR 2.62,P < .001),SHM与更差的PFS相关(HR 5.01,P < .001)。
- SPM与更差的OS相关(HR 3.85,P < .001),SHM与更差的OS相关(HR 8.13,P < .001)。
- 在发生SPM和SHM的患者中,多发性骨髓瘤仍是最常见的首要死因(分别为42% vs 30%和53% vs 18%)。
临床怎么用
- 作者认为SPM和SHM导致多发性骨髓瘤患者生存不良,是重要的生存挑战。
- 作者指出鉴于骨髓瘤中位生存持续改善,需持续警惕auto-HSCT后维持治疗相关的SPM和SHM风险。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The overall survival (OS) has improved significantly in multiple myeloma (MM) over the last decade with the use of proteasome inhibitor and immunomodulatory drug-based combinations, followed by high-dose melphalan and autologous hematopoietic stem cell transplantation (auto-HSCT) and subsequent maintenance therapies in eligible newly diagnosed patients. However, clinical trials using auto-HSCT followed by lenalidomide maintenance have shown an increased risk of second primary malignancies (SPM), including second hematological malignancies (SHM). We evaluated the impact of SPM and SHM on progression-free survival (PFS) and OS in patients with MM after auto-HSCT using CIBMTR registry data. Adult patients with MM who underwent first auto-HSCT in the United States with melphalan conditioning regimen from 2011 to 2018 and received maintenance therapy were included (n = 3948). At a median follow-up of 37 months, 175 (4%) patients developed SPM, including 112 (64%) solid, 36 (20%) myeloid, 24 (14%) SHM, not otherwise specified, and 3 (2%) lymphoid malignancies. Multivariate analysis demonstrated that SPM and SHM were associated with an inferior PFS (hazard ratio [HR] 2.62, P < .001 and HR 5.01, P < .001, respectively) and OS (HR 3.85, P < .001 and HR 8.13, P < .001, respectively). In patients who developed SPM and SHM, MM remained the most frequent primary cause of death (42% vs 30% and 53% vs 18%, respectively). We conclude the development of SPM and SHM leads to a poor survival in patients with MM and is an important survivorship challenge. Given the median survival for MM continues to improve, continued vigilance is needed to assess the risks of SPM and SHM with maintenance therapy post-auto-HSCT.
引用
- Ragon BK, Shah MV, D'Souza A, et al. Impact of second primary malignancy post-autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis. Blood Adv. 2023. PMID: 36827681. doi:10.1182/bloodadvances.2022009138
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。